

# Efficacy of the treatment with a COX-2 specific inhibitor celecoxib in osteoarthritic patients

<b>Submission date</b> 06/07/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 08/07/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 02/10/2008	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Javier Santillana

**Contact details**  
Orthopaedic Department  
Hospital de Tortosa Virgen de la Cinta  
Esplanetes 47  
Tortosa - Tarragona  
Spain  
43500  
+34 977519133  
jsanmher@eresmas.com

## Additional identifiers

## Study information

**Scientific Title**

**Acronym**  
COXOA

**Study objectives**

Our hypothesis is that celecoxib could have a specific antiinflammatory profile to that of a classic antiinflammatory treatment on patients with knee osteoarthritis (OA).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Advanced osteoarthritis

**Interventions**

Comparison of celecoxib treatment versus aceclofenac treatment

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Celecoxib and aceclofenac

**Primary outcome(s)**

Synovial inflammation markers on the synovial membrane of osteoarthritis patients

**Key secondary outcome(s)**

Effect on Western Ontario McMaster Universities Osteoarthritis (WOMAC) index

**Completion date**

12/02/2003

**Eligibility****Key inclusion criteria**

Patients with clinical and radiological evidence of knee OA who met the American Rheumatism Association criteria for functional classes III or IV, who were scheduled for total knee replacement and who accepted to be treated with an antiinflammatory drug.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

Pregnancy, gastrointestinal pathology, kidney or hepatic insufficiency, diabetes, cardiovascular disease, oncologic patients.

**Date of first enrolment**

12/02/2002

**Date of final enrolment**

12/02/2003

**Locations****Countries of recruitment**

Spain

**Study participating centre****Orthopaedic Department**

Tortosa - Tarragona

Spain

43500

**Sponsor information****Organisation**

Hospital de Tortosa Virgen de la Cinta (Spain)

**ROR**

<https://ror.org/046sqxa62>

**Funder(s)**

## Funder type

Industry

## Funder Name

Mapfre Medicina Foundation (grant 2003), Spanish Ministry of Education (SAF 08/0379), Fondo de Investigaciones Sanitarias (CP03/00011), Pfizer Spain

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/12/2008		Yes	No